1 Oh M, "Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy" 53 : 399-406, 2012
2 Djang DS, "SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0" 53 : 154-163, 2012
3 Spencer TJ, "PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short-and long-acting oral methylphenidate" 163 : 387-395, 2006
4 Vles JS, "Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder(ADHD)" 34 : 77-80, 2003
5 Booij J, "Dopamine transporter imaging with [(123)I]FP-CIT SPECT : potential effects of drugs" 35 : 424-438, 2008
6 Kraemmer J, "Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts" 29 : 1767-1773, 2014
7 Diaz-Corrales FJ, "Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease" 37 : 556-564, 2010